EXELIXIS INC's ticker is EXEL and the CUSIP is 30161Q104. A total of 376 filers reported holding EXELIXIS INC in Q2 2022. The put-call ratio across all filers is 0.21 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2024 | $10 | -9.1% | 466 | 0.0% | 0.00% | – |
| Q1 2024 | $11 | 0.0% | 466 | -2.1% | 0.00% | – |
| Q4 2023 | $11 | 0.0% | 476 | 0.0% | 0.00% | – |
| Q3 2023 | $11 | +10.0% | 476 | -8.1% | 0.00% | – |
| Q2 2023 | $10 | +100.0% | 518 | +108.9% | 0.00% | – |
| Q1 2023 | $5 | +66.7% | 248 | +28.5% | 0.00% | – |
| Q4 2022 | $3 | -99.9% | 193 | -11.5% | 0.00% | – |
| Q3 2022 | $3,000 | +200.0% | 218 | +772.0% | 0.00% | – |
| Q2 2022 | $1,000 | -95.7% | 25 | -98.1% | 0.00% | – |
| Q3 2019 | $23,000 | -17.9% | 1,308 | 0.0% | 0.00% | – |
| Q2 2019 | $28,000 | +1300.0% | 1,308 | +262.3% | 0.00% | – |
| Q3 2015 | $2,000 | -92.3% | 361 | -96.4% | 0.00% | – |
| Q1 2015 | $26,000 | +85.7% | 10,000 | 0.0% | 0.00% | – |
| Q4 2014 | $14,000 | -53.3% | 10,000 | -50.0% | 0.00% | – |
| Q3 2014 | $30,000 | – | 20,000 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Meditor Group Ltd | 11,275,871 | $254,722,000 | 71.55% |
| GREAT POINT PARTNERS LLC | 1,201,100 | $27,133,000 | 5.61% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 886,534 | $20,027,000 | 5.30% |
| Sargent Investment Group, LLC | 498,350 | $11,258,000 | 2.96% |
| CAPITAL MANAGEMENT CORP /VA | 311,660 | $7,040,000 | 1.57% |
| EULAV Asset Management | 2,460,000 | $55,571,000 | 1.49% |
| CM Management, LLC | 80,000 | $1,807,000 | 1.34% |
| Integral Health Asset Management, LLC | 200,000 | $4,518,000 | 1.29% |
| FARALLON CAPITAL MANAGEMENT LLC | 10,750,000 | $242,843,000 | 1.21% |
| Sofinnova Investments, Inc. | 839,181 | $18,957,000 | 1.14% |